Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Common Equity (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Common Equity for 8 consecutive years, with $157.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 128.22% to $157.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $157.2 million, a 128.22% increase, with the full-year FY2024 number at $52.5 million, down 50.11% from a year prior.
  • Common Equity was $157.2 million for Q3 2025 at Whitehawk Therapeutics, down from $172.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $221.7 million in Q1 2025 to a low of -$19.4 million in Q2 2021.
  • A 5-year average of $113.3 million and a median of $124.6 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 836.54% in 2021, then tumbled 50.11% in 2024.
  • Whitehawk Therapeutics' Common Equity stood at $136.4 million in 2021, then rose by 16.11% to $158.4 million in 2022, then crashed by 33.58% to $105.2 million in 2023, then crashed by 50.11% to $52.5 million in 2024, then skyrocketed by 199.49% to $157.2 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Common Equity are $157.2 million (Q3 2025), $172.1 million (Q2 2025), and $221.7 million (Q1 2025).